Orthoxine : a potent sympathomimetic agent for the prevention and treatment of bronchial asthma an orally effective chemical entity singularly specific as a bronchodilator singularly free from side effects / a significant development of the Upjohn Research Laboratories.

  • Upjohn of England.
Date:
[1948?]
Catalogue details

Licence: Public Domain Mark

Credit: Orthoxine : a potent sympathomimetic agent for the prevention and treatment of bronchial asthma an orally effective chemical entity singularly specific as a bronchodilator singularly free from side effects / a significant development of the Upjohn Research Laboratories. Source: Wellcome Collection.

    2/4
    \ Hundreds of drugs were studied and large series of new amines synthesized in Upjohn’s search for a new sympathomimetic, an orally effective bronchodilator singularly free from pressor activity, “a drug with a single track mind,” an effective substitute for ephedrine. Of all those synthesized and of all those studied—the compound beta-(ortho-methoxypheny])-isopropyl-methylamine hydrochloride— O R ok H O xX I N 1D Hydrochloride was chosen. Discriminating laboratory and clinical procedures demonstrate Orthoxine to be the first sympathomimetic whose major activity is primarily bronchodilation; as such, it has many clinical advantages, particularly for BRONCHIAL ASTHMA A PRIMARY BRONCHODILATOR which is selectively effective in relieving broncho-constriction being singularly free from the common vasopressor, cardiac and central nervous side effects characteristic of all sympathomimetic “‘pressor’’ amines and so safe as to be suitable for repeated use even in the presence of hypertension Now available to prevent and treat successfully the overwhelming bulk of bronchial asthma—the moderate and mild types. WELLCOME INSTITUTE MY AH YU | | Wh 22 500
    digitised image 1
    digitised image 2
    digitised image 3